New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTNBS, PSTI, CUR, OSIR, BCLI, ATHXRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
09:23 EDTCURNeuralstem announces approving for listing on Nasdaq
Subscribe for More Information
June 26, 2015
07:33 EDTCURNeuralstem announces preclinical data of HK532-IGF-1 stem cells
Neuralstem announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research Annual Meeting. In the poster, researchers from the University of Michigan presented data that mice with an animal model of Alzheimer's disease, transplanted with HK532-IGF-1 cells in the peri-hippocampus, performed better on hippocampal-dependent behavioral tasks than untreated mice, demonstrating both enhanced learning cognitive processes and memory consolidation. Researchers also reported a beta-amyloid plaque reduction in both the cortex and hippocampus of the mice that received the stem cells. Amyloid plaque is one of the two hallmarks of AD. These results indicate that HK532-IGF-1 transplantation can impact learning and memory deficits, as well as Alzheimer's pathology. The researchers found the results to be encouraging and recommend further study. HK532-IGF-1, Neuralstem's second stem cell line, is a proprietary line of cortical neural stem cells engineered to express insulin-like growth factor-1, which has been shown to have wide-ranging neuroprotective properties.
June 25, 2015
09:52 EDTPSTIPluristem raises $17M in a registered direct offering
Subscribe for More Information
June 24, 2015
05:30 EDTPSTIPluristem granted Australian patent for 3D cell expansion technology
Pluristem Therapeutics announced that it has been granted an Australian patent titled "Adherent Cells From Placenta Tissue and Use Thereof in Therapy". Patent #2009288781 covers Pluristem's proprietary, three-dimensional method of growing cells from placental or adipose tissue, cells produced by the process, and the use of such cells in the potential treatment of a broad range of conditions. These include peripheral artery disease, other ischemic and cardiovascular diseases, graft-versus-host disease, organ transplantation, cancer, and autoimmune diseases. The patent term will extend until 2027.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use